Understanding Opioid Addiction and Relpase Risks for Patients in an Office Based Buprenorphine Treatment Program by Carlson, Rachel E
University of Vermont
ScholarWorks @ UVM
Family Medicine Clerkship Student Projects College of Medicine
2016
Understanding Opioid Addiction and Relpase




Follow this and additional works at: http://scholarworks.uvm.edu/fmclerk
Part of the Medical Education Commons, and the Primary Care Commons
This Book is brought to you for free and open access by the College of Medicine at ScholarWorks @ UVM. It has been accepted for inclusion in Family
Medicine Clerkship Student Projects by an authorized administrator of ScholarWorks @ UVM. For more information, please contact
donna.omalley@uvm.edu.
Recommended Citation
Carlson, Rachel E., "Understanding Opioid Addiction and Relpase Risks for Patients in an Office Based Buprenorphine Treatment
Program" (2016). Family Medicine Clerkship Student Projects. Book 151.
http://scholarworks.uvm.edu/fmclerk/151
UNDERSTANDING OPIOID ADDICTION 
AND RELAPSE RISKS FOR PATIENTS IN 
AN OFFICE BASED BUPRENORPHINE 
TREATMENT PROGRAM 
UNDER THE SUPERVISION OF DR. JESSICA BLOOM-FOSTER MD
EMMC CENTER FOR FAMILY MEDICINE RESIDENCY PROGRAM
PROJECT BY : RACHEL CARLSON C/O 2018




• Efforts to improve pain management in the 1990s by prescribing opioids has lead to an increase 
in opioid addiction. Opioid use has also correlated with the rising use of heroin. [1] 
• A majority of treatment programs including buprenorphine and methadone are located in urban 
areas increasing the challenge for rural patients to seek and remain in treatment. [2]
• The EMMC Center for Family Medicine has a buprenorphine treatment program enrolling over 
200 patients from both urban and rural areas surrounding Bangor.
• Several risk factors for relapse on buprenorphine treatment have been identified including 
comorbid anxiety disorders, active benzodiazepine use, or active alcohol abuse. However most of 
these studies focus on urban population. [3]
• It is important to identify risks for relapse and challenges to treatment in the unique population 
served at EMMC CFM in Bangor 
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PUBLIC HEALTH COST
• 1 of every 550 patients started on opioid therapy died of opioid related causes a 
median of 2.6 years after the first opioid prescription; the proportion was as high as 
1 in 32 among patients receiving doses of 200 MME or higher [1]
In Maine: 
• 7% adults ages 18-35 report misusing prescription drugs within their lifetime [4]
• 272 deaths in 2015 are attributed to substance abuse rising from 208 in 2014 [4]
• In 2014  7 out of 10 overdose deaths involved on opiate or opioid- 1in 3 involved a 
benzodiazepine- 1in 4  involved heroin- 1in 5 involved oxycodone or fentanyl [4]
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COMMUNITY PERSPECTIVE
Matthew Nutt LCSW CCS: Behavioral Medicine Counselor
Patricia Kimball LADC, CCS: Executive Director of Wellspring Substance Abuse and Mental Health 
Services
• How do your see substance abuse impacting this community
• MN: “It is killing people. So many are profoundly impacted by the loss of life as the death toll rises”
• PK: “It infiltrates everywhere. From law enforcement, crime, poverty….it is destroying families and the 
workforce”
• What are the biggest challenges each face while in treatment?
• MN: “Number one is patients being honest with providers. Patients think will I get kicked out of treatment or 
loose my kids if I admit to a slip….Second is being able to afford treatment and another is having the 
transportation and funds to get to appointments each week.”
• PK: “Patients struggle with the illness itself and maintaining sobriety. Many struggle and fail in jobs and have 
trouble getting loans and housing because of their previous actions while using.
• What are the biggest risks for relapse?
• MN: “past relationships involving using….more challenging when family is using. Also feelings, stress, and 
boredom”
• PK: Not having a sober support system, housing- not asking for help- and challenged by self regulation 
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INTERVENTION WITH METHODOLOGY
• Goal: To gain a greater understanding of relapse risks for patients undergoing 
office based buprenorphine treatment at EMMC CFM.
• Methodology: 
• Completed a retrospective chart analysis of at risk behaviors and 6 month relapse occurrence
• Surveyed EMMC CFM providers assessing physician perceived risks for relapse
• Created patient centered discussion questions to explore barriers to treatment and patient 
perceived risk factors for relapse
• Intervention
• Data from Chart analysis will be compiled and analyzed for current research by Dr. Jessica 
Bloom-Foster MD, Faculty at EMMC CFM
• Lead group session with patients in treatment identifying risks for relapse and barriers to 





Mean Age Use Began 18.3
Percent Female 80%
Percent Pregnant 69%
Total Relapse (N=6) 30%






























Months To Relapse Partner Status of
Patients in Recovery at 6 months
Sober None Abusing In treatment
Partner Status of 
Relapsed Patients 
Sober None Abusing In Treatment
• Retrospective Chart Analysis 
Completed for N=20
• Analyzed: substance abuse hx, mental 
health diagnoses, and urine 
toxicology screens.
• Strongest correlation to relapse 
existed with partner abusing drugs 
status. (abusing=drug abuse)
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RETROSPECTIVE CHART ANALYSIS DISCUSSION
• Total Relapse of 30% was consistent with previously collected data
• There was a strong correlation between partner use and relapse
• Pregnancy appeared to be a protective factor from relapsing. Pregnancy could be a 
motivational factor for change and remaining in treatment or current program 
structure is more flexible with allowing treatment to continue in pregnant patients 
who may have displayed problem behaviors
• After our discussion with patients and providers, transportation and travel distance to 
treatment was identified as a potential risk factor for relapse. Future studies could 
examine this factor in greater detail. 
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RESULTS: 
PROVIDER AND PATIENT PERSPECTIVE OF RISKS TO RELAPSE 
Patient Centered Discussion
- What are some of the biggest risk for relapse
Old friends
Long distance to clinic
Stress/ Boredom 
Being able to afford treatment 
Judgement from providers
- What are some strategies to help people start treatment and 
remain in treatment 
Support and encouragement from loved ones 
Knowing when you need help
Change scenery- Move away
Peer support group
- What is your quality of life since being in treatment  
I have hope 
Feel like I have a future





Risk of relapse if partner is using opioids 




Risk of relapse if missed 5 or more counseling 
appointments 
1(Lowest Risk) 2 3 4 5 (Highest Risk)
Provider Perceived Relapse Risk 
(N=23)
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EVALUATE EFFECTIVENESS AND LIMITATIONS
• Effectiveness:
• Expanded retrospective chart analysis data to be included in future grant proposal
• Identified partner drug use as significant risk for relapse
• Gathered qualitative data involving patient perceived risk factors to explore future intervention strategies 
including challenges with transportation and affordability
• Determined risks for relapse perceived by physicians were consistent with chart analysis risks for relapse 
including increase in missed appointments and partner use. 
• Limitations
• Did not have time for IRB Approval Process and was unable to conduct a formal group interview of patients 
• Males were underrepresented in study population 
• Study population did not look at transportation or distance from clinic which were two factors repeatedly 
discussed by providers and patients as perceived risk factors 
• Small sample size for both patient and provider surveys were impacted by timing constraint
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RECOMMEND FUTURE
• Encourage physicians and staff to be open, honest, and nonjudgmental when working 
with patients in buprenorphine treatment. 
• Obtain IRB approval to conduct a formal qualitative interview of patients 
undergoing treatment to gather expanded information on prevention strategies for 
relapse 
• Include transportation, travel distance to clinic, and ability to pay to determine if 
these factors influence relapse- particularly with Bangor serving both an urban and 
rural population.
• Search for alternative treatment for partners still abusing as EMMC CFM has 
reached capacity and is open to pregnant patients at this time. 
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INTERVIEW CONSENT 
• Thank you for agreeing to be interviewed. This project is a requirement for the Family 
Medicine clerkship. It will be stored on the Dana Library ScholarWorks website. Your name 
will be attached to your interview and you may be cited directly or indirectly in subsequent 
unpublished or published work. The interviewer affirms that he/she has explained the nature 
and purpose of this project. The interviewee affirms that he/she has consented to this 
interview. Yes __X___ / No _____ 
• Name: Patricia Kimball: Executive Director of Substance Abuse and Mental Health Services
• Name: Matthew Nutt LCSW CCS: Behavioral Medicine Counselor 
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